Cointime

advanceCOR

company

About

advanceCOR is a clinical drug developing company that focuses on therapeutics and diagnostics for heart and vascular diseases.

  • 1 - 10

Highlights

Total Funding Amount
€6M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
€6M
Industries
Biotechnology
Founded date
Jan 1, 2012
Number Of Employee
1 - 10
Operating Status
Active

advanceCOR is a clinical drug developing company that focuses on therapeutics and diagnostics for heart and vascular diseases. Its products include Revacept, a human Fc fusion protein, which prevents the local activation of platelets at sites of vascular injury; COR-2, a recombinant protein that interferes with the generation of foam cells; and COR-3, a recombinant protein, which specifically binds to atherosclerotic plaques, and then bi-specifically binds to circulating progenitor cells to trap the endogenously occurring progenitor cells for accelerated plaque healing.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€6M
advanceCOR has raised a total of €6M in funding over 2 rounds. Their latest funding was raised on May 21, 2018 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 21, 2018 Series Unknown €6M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
advanceCOR is funded by 1 investors. Bayern Kapital are the most recent investors.
Investor Name Lead Investor Funding Round
Bayern Kapital — Series Unknown
Cointime
Содержание
компания